1990至2019年204个国家气管支气管肺癌负担及其归因风险因素
该研究基于癌症登记、生命登记和口头尸检等数据,估算1990至2019年204个国家气管、支气管和肺癌的发病率、死亡率和伤残调整寿命年(DALY)。部分国家负担上升,吸烟、环境颗粒物和高空腹血糖是主要归因因素。
要点
- 全球TBL癌症年龄标化发病率、死亡率和DALY率在1990至2019年间均下降。
- 格陵兰、摩纳哥和黑山年龄标化发病、死亡和DALY率最高。
- 吸烟(62.4%)、环境颗粒物(15.3%)和高空腹血糖(9.9%)是主要归因DALY因素。
核心结论
- 全球TBL癌症负担总体下降,但部分国家发病、死亡和DALY标化率上升。
研究设计与样本
- 基于癌症登记(5318站点-年)、生命登记(22553站点-年)、生命登记样本(825站点-年)和口头尸检(516站点-年)数据估算204个国家1990至2019年TBL癌症负担。
主要发现
- 格陵兰(77.7 [95%UI 64.4-90.6])、摩纳哥(75.6 [95%UI 61.4-90.8])和黑山(56.7 [95%UI 46.5-68.9])年龄标化发病率最高,且死亡和DALY标化率也最高。
- 洪都拉斯(68% [95%UI 14.5-137.7])、佛得角(62.2% [95%UI 24.1-101.3])和摩纳哥(58.2% [95%UI 19.2-109.7])年龄标化发病率增幅最大;洪都拉斯(67.1% [95%UI 14.7-133.1])、佛得角(64.4% [95%UI 25-103.4])和莫桑比克(49.9% [95%UI 7.9-101.3])年龄标化死亡率增幅最大。
临床怎么用
- 临床医生应关注TBL癌症全球负担下降但部分国家上升的趋势,在上升地区加强预防和筛查。
- 针对吸烟、环境颗粒物和高空腹血糖等可干预风险因素,在临床实践中开展患者教育和风险管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Understanding trends in the annual incidence, mortality, and disability-adjusted life-years (DALYs) for tracheal, bronchus, and lung (TBL) cancer globally is important to enable appropriate targeting of resources for prevention, clinical practice improvement, and research. The aim of this study was to determine the global, regional, and national burdens of TBL cancer in 204 countries and territories from 1990 to 2019 by age, sex, and sociodemographic index. METHODS: Estimates were produced through various data inputs including the following: cancer registries (nsite-years = 5318), vital registration (nsite-years = 22,553), vital registration-sample (nsite-years = 825), and verbal autopsies (nsite-years = 516). Annual incidence, mortality, and DALYs were estimated and presented as counts and age-standardized rates per 100,000 population. RESULTS: There were 2.3 million (95% uncertainty interval [UI]: 2.1-2.5) incident cases of TBL cancer, with an age-standardized annual incidence rate of 27.7 (95% UI: 25.3-30), which decreased by 2.6% (95% UI: -12.4 to 6.5) between 1990 and 2019. TBL cancer was responsible for 2 million (95% UI: 1.9-2.2) deaths globally with an age-standardized death rate of 25.2 (95% UI: 23.2-27), a decrease of 7.8% (95% UI: -15.9 to 0.2) between 1990 and 2019. Moreover, TBL accounted for 45.9 million (95% UI: 42.3-49.3) DALYs at the global level, with an age-standardized rate of 551.6 (95% UI: 509-593.1) DALYs per 100,000 population. The standardized DALY rate declined by 16.2% (95% UI: -24 to -8.2) from 1990 to 2019. Greenland (77.7 [95% UI: 64.4-90.6]), Monaco (75.6 [95% UI: 61.4-90.8]), and Montenegro (56.7 [95% UI: 46.5-68.9]) had the three highest age-standardized annual incidence rates. The aforementioned three countries also had the three highest age-standardized death and DALY rates of TBL cancer. Honduras (68% [95% UI: 14.5-137.7]), Cabo Verde (62.2% [95% UI: 24.1-101.3]), and Monaco (58.2% [95% UI: 19.2-109.7]) had the largest increase in age-standardized annual incidence rates for TBL cancer during 1990 to 2019. The largest increases were found in age-standardized death rates of TBL cancer in Honduras (67.1% [95% UI: 14.7-133.1]), Cabo Verde (64.4% [95% UI: 25-103.4]), and Mozambique (49.9% [95% UI: 7.9 -101.3]). Age-standardized annual incidence and death rates were higher in male than female individuals and increased with population aging. There were nonlinear but generally positive associations between age-standardized DALY rates with corresponding sociodemographic index of countries. Globally, smoking (62.4%), ambient particulate matter (15.3%), and high fasting plasma glucose (9.9%) had the top three highest percent of attributable DALYs owing to TBL cancer in 2019 for both sexes. CONCLUSIONS: This study found a decline in burden globally but with some countries having an increase. These results are crucial to set priorities for prevention and treatment of TBL cancer and would be beneficial for policymakers, government officials, clinicians, and researchers.
引用
- Safiri S, Sohrabi MR, Carson-Chahhoud K, et al. Burden of Tracheal, Bronchus, and Lung Cancer and Its Attributable Risk Factors in 204 Countries and Territories, 1990 to 2019. J Thorac Oncol. 2021. PMID: 33866016. doi:10.1016/j.jtho.2021.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。